Cargando…

LGG-28. Rapid symptomatic improvement for a patient treated with BRAF inhibition for BRAFV600E mutated ganglioglioma

BACKGROUND: Biologically targeted agents such as the BRAF inhibitor dabrafenib are now used to treat progressive low-grade glioma (LGG), but the effect of these agents on the neurologic symptoms that accompany LGGs is poorly understood. CASE: A 21-year-old male was diagnosed with medullary gangliogl...

Descripción completa

Detalles Bibliográficos
Autores principales: Cantor, Evan, Cochrane, Anne, Morris, Stephanie, Meyer, Ashley, Ogle, Andrea, Shatara, Margaret, Cluster, Andrew, Deng, Mai, Abdelbaki, Mohamed S, Brossier, Nicole M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9165172/
http://dx.doi.org/10.1093/neuonc/noac079.720